Mesenchymal stem cell therapy in hematopoietic stem cell transplantation

DOI Web Site PubMed
  • GOTO Tatsunori
    Department of Hematology, Nagoya University Hospital
  • MURATA Makoto
    Department of Hematology and Oncology, Nagoya University Graduate School of Medicine

Bibliographic Information

Other Title
  • 造血幹細胞移植における間葉系幹細胞を用いた細胞療法
  • ゾウケツ カンサイボウ イショク ニ オケル カンヨウケイ カンサイボウ オ モチイタ サイボウ リョウホウ

Search this article

Abstract

<p>Mesenchymal stem cells (MSCs) have received considerable attention in allogeneic hematopoietic cell transplantation because of their abilities to modulate immune responses and promote hematopoiesis. Because MSCs are capable of producing several cytokines and growth factors, they have been widely used in the treatment of graft-versus-host disease (GVHD). A number of clinical trials have demonstrated the safety and efficacy of MSC therapy for acute GVHD. Moreover, in Japan, allogeneic bone marrow-derived MSC product, TEMCELL®, was approved as a regenerative medicine for acute GVHD. Besides, MSCs can also produce bone marrow stroma and promote hematopoiesis, the co-transplantation of hematopoietic stem cells and MSCs have been efficiently performed in cord blood transplantation and HLA-mismatched transplantation to enhance engraftment and prevent GVHD. In this review, we provide an overview of clinical trials using MSCs in allogeneic hematopoietic cell transplantation and discuss the possibilities and optimization of MSC therapy.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 59 (2), 195-204, 2018

    The Japanese Society of Hematology

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top